Alerts will be sent to your verified email
Verify EmailJBCHEPHARM
JB Chem & Pharma
|
Wockhardt
|
Pfizer
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
19.0 . | n/a | n/a |
Number of ANDA's Approved By USFDA
|
17.0 . | n/a | n/a |
Domestic Sales Growth - YoY
|
10.1 % | 10.6 % | 4.8 % |
R&D as a % of Total Sales
|
1.35 % | 3.7 % | n/a |
Financials
|
|||
5 yr Average ROE
|
19.49 % | -3.51 % | 19.03 % |
5yr average Equity Multiplier
|
1.52 | 2.02 | 1.25 |
5yr Average Asset Turnover Ratio
|
0.77 | 0.39 | 0.6 |
5yr Avg Net Profit Margin
|
16.71 % | -4.28 % | 26.04 % |
Price to Book
|
7.82 | 5.69 | 5.78 |
P/E
|
39.17 | 0.0 | 30.13 |
5yr Avg Cash Conversion Cycle
|
7.58 Days | -94.15 Days | 21.86 Days |
Inventory Days
|
50.33 Days | 61.29 Days | 49.93 Days |
Days Receivable
|
67.54 Days | 60.36 Days | 29.1 Days |
Days Payable
|
90.39 Days | 251.45 Days | 77.28 Days |
5yr Average Interest Coverage Ratio
|
58.81 | -0.43 | 185.18 |
5yr Avg ROCE
|
23.05 % | -0.28 % | 23.84 % |
5yr Avg Operating Profit Margin
|
24.73 % | 5.03 % | 31.72 % |
5 yr average Debt to Equity
|
0.07 | 0.56 | 0.0 |
5yr CAGR Net Profit
|
8.05 % | n/a | 76.68 % |
5yr Average Return on Assets
|
12.98 % | -1.79 % | 15.25 % |
Shareholdings
|
|||
Promoter Holding
|
47.73 % | 49.09 % | 63.92 % |
Share Pledged by Promoters
|
0.0 | 15.64 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-6.27 % | -16.66 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
1.15 % | 7.99 % | 4.53 % |
JB Chem & Pharma
|
Wockhardt
|
Pfizer
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|